Dr. Scheller, who served at 23andMe for four years, has left the company to join biotechnology company BridgeBio as chairman of research and development. He will remain on 23andMe’s board of directors.
Kenneth Hillan, 23andMe’s head of therapeutics, will take over Dr. Scheller’s responsibilities but not his title, according to the report.
23andMe announced in March 2015 that it would begin to develop drugs. According to its website, the company is working on treatments for cancer and diseases that affect the skin, lungs and heart.
Read the full report here.
More articles on pharmacy:
Judge blocks HHS rule requiring drug prices in TV ads
Nation’s 1st prescription drug affordability board goes into effect
11 healthcare pharma leaders offer advice on controlling drug spend
